Tolebrutinib – A New Era of MS Treatments Targeting Progression in Non-Relapsing MS
Tolebrutinib is the first and only disease modifying therapy (DMT) showing positive signs of slowing progression in non-relapsing secondary progressive MS (SPMS). While current DMTs focus on dampening the inflammatory aspects of MS, this significant breakthrough heralds a potential new era of therapies which look to target the underlying progression in MS. Currently in NZ, […]